Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Alembic Pharmaceuticals commissions new facility at Pithampur
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
USFDA inspection at Alembic Pharma's Bioequivalence facility
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Subscribe To Our Newsletter & Stay Updated